MedTrace Logo

Ribomustin in the Second Line Therapy of Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma

NCT02072967 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 97

Last updated 2016-02-22

No results posted yet for this study

Summary

Prospective multicenter observational non-interventional study to assess routine clinical practice of Bendamustine use in the second line therapy of relapsed or refractory indolent B-cell non-Hodgkin's lymphoma

Conditions

  • Lymphoma, Non-Hodgkin

Interventions

OTHER

Ribomustin

Routine practice

OTHER

rituximab

Routine practice

Sponsors & Collaborators

  • Astellas Pharma Europe B.V.

    lead INDUSTRY

Principal Investigators

  • Clinical Study Manager · Astellas Pharma Europe B.V.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2015-10-31
Completion
2015-10-31

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02072967 on ClinicalTrials.gov